Capricor Therapeutics Faces Class Action Over Alleged Securities Fraud in Deramiocel Clinical Data

Capricor Therapeutics Under Legal Scrutiny Amid Class Action

In recent developments, Capricor Therapeutics, Inc. is facing a class action lawsuit filed by investors alleging securities fraud, stemming from discrepancies in clinical data regarding their flagship product, Deramiocel. This biotech company, which focuses on cellular and exosome-based therapeutics for rare diseases, is currently under significant scrutiny following a startling drop in its stock price.

Overview of the Legal Action

The lawsuit has been brought forward by the law firm Bleichmar Fonti & Auld LLP on behalf of investors, following a staggering 64.5% decrease in Capricor’s stock on July 27, 2026. This drop was reportedly triggered by concerns raised by the FDA concerning the integrity of clinical data related to Deramiocel, which is primarily developed for the treatment of Duchenne muscular dystrophy (DMD).

According to court documents, Capricor allegedly made false statements about the reliability of its clinical data submitted in their Biologics License Application (BLA) to the FDA. The complaint asserts that Capricor failed to disclose modifications to its pre-specified statistical analysis plan, which was not approved by the FDA prior to its BLA resubmission. These purported omissions have led to legal claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Key Events Leading to the Lawsuit

The FDA Response

In late 2024, Capricor submitted its BLA for Deramiocel but faced a setback when the FDA issued a Complete Response Letter in July 2025, indicating that the application fell short of demonstrating substantial evidence of the drug’s efficacy. The agency highlighted the need for additional clinical data, leading to a pivot in Capricor's strategy.

On July 27, 2026, just before a crucial advisory committee meeting, the FDA released briefing documents that raised significant concerns about changes Capricor made to its statistical analysis plan. These adjustments were criticized for being executed shortly before crucial data were unblinded, igniting fears about the data's reliability. As a consequence, Capricor's stock plummeted from a robust closing price of $19.70 per share on July 24, 2026, to a mere $7.00 on July 27, 2026.

Subsequent Stock Reactions

Following the July 29, 2026, FDA advisory committee meeting, the situation worsened for Capricor. Reports indicated a non-binding vote of 9-3 against the available evidence supporting Deramiocel’s efficacy, further exacerbating investor panic. This news precipitated another decline, with the stock falling to $4.19 per share by July 30, 2026.

What This Means for Investors

Investors impacted by this drastic decline now have until September 28, 2026, to seek appointment as lead plaintiffs in the class action. The legal firm emphasizes that representation is on a contingency fee basis, implying that shareholders will not shoulder any costs for litigation unless there is a recovery.

For those who invested in Capricor, avenues for recourse are available through the active legal proceedings. Interested parties are encouraged to visit the law firm's dedicated page for the Capricor class action for further information on their rights and the legal framework of the lawsuit.

Conclusion

As Capricor Therapeutics navigates this legal challenge, the outcome of the class action could have significant implications not only for the company but also for the broader biotech industry. The developments surrounding Deramiocel signal a critical juncture as regulatory agencies continue to press for transparency and accuracy in clinical data reporting. Investors are poised to watch closely as this case unfolds, aware that the integrity of clinical trials and subsequent communications is paramount in maintaining trust in biotech innovations.